Suramin Sodium
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Jun 1, 2019 → Mar 15, 2021
NCT ID
NCT06058962About Suramin Sodium
Suramin Sodium is a phase 2 stage product being developed by PaxMedica for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT06058962. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06058962 | Phase 2 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder